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Abstract  There  are  currently  no  reliable  instruments  for  assessing  the  onset  and  progres-
sion of  chronic  obstructive  pulmonary  disease  (COPD)  or  predicting  its  prognosis.  Currently,
a comprehensive  assessment  of  COPD  including  several  objective  and  subjective  parameters
is recommended.  However,  the  lack  of  biomarkers  precludes  a  correct  assessment  of  COPD
severity, which  consequently  hampers  adequate  therapeutic  approaches  and  COPD  control.  In
the absence  of  a  deﬁnition  of  ‘‘well-controlled  disease’’,  a  consensus  regarding  COPD  control
will be  difﬁcult  to  reach.  However,  COPD  patient  assessment  should  be  multidimensional,  and
anchored in  ﬁve  points:  control  of  symptoms,  decline  of  pulmonary  function,  levels  of  physical
activity, exacerbations,  and  Quality  of  Life.
Several  non-pharmacological  and  pharmacological  measures  are  currently  available  to
achieve disease  control.  Smoking  cessation,  vaccination,  exercise  training  programs  and
pulmonary  rehabilitation  are  recognized  as  important  non-pharmacological  measures  but  bron-
chodilators are  the  pivotal  therapy  in  the  control  of  COPD.  This  paper  discusses  several  objective
and subjective  parameters  that  may  bridge  the  gap  between  disease  assessment  and  disease
control.  The  authors  conclude  that,  at  present,  it  is  not  possible  to  reach  a  consensus  regarding
COPD control,  essentially  due  to  the  lack  of  objective  instruments  to  measure  it.  Some  recom-
mendations  are  set  forth,  but  true  COPD  control  awaits  further  objective  assessments.
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ntroduction
raditionally,  spirometry  has  been  used  to  assess  Chronic
bstructive  Pulmonary  Disease  (COPD)  severity  and  guide
reatment,  but  a  growing  body  of  evidence  documenting
 poor  correlation  between  forced  expiratory  volume  in  1
econd  (FEV1)  and  symptoms  or  Quality  of  Life  (QoL)  in
OPD  patients,1--5 raises  doubts  as  to  the  real  effectiveness
f  spirometry  as  an  instrument  for  assessing  COPD  control.
urrently,  several  tools  are  recommended  for  a  comprehen-
ive  evaluation  of  COPD,  and  although  some  are  objective
easurements,  many  remain  subjective,  such  as  question-
aires  for  symptoms  or  QoL  assessment.5--12 This  hampers
OPD  control:  how  can  we  deﬁne  a  well-controlled  patient
f  a  proper  assessment,  encompassing  all  its  dimensions,
s  not  currently  attainable?  Despite  the  existence  of  sev-
ral  pharmacological  and  non-pharmacological  approaches
o  the  management  of  COPD,  there  is  a  clear  need  to  bridge
he  gap  between  disease  assessment  and  disease  control.
his  paper  discusses  several  objective  and  subjective  param-
ters  that  may  make  part  of  that  bridge.
OPD: an evolving concept
he  ﬁrst  reference  to  COPD  dates  back  to  the  XVII  cen-
ury,  in  the  writings  of  Theophile  Bonet,  where  he  described
he  effects  of  lung  emphysema  as  ‘‘voluminous  lungs’’.13
owever,  only  almost  three  centuries  later,  in  1944,  Ronald
hristie  wrote  in  the  British  Medical  Journal  that  ‘‘[.  . .] the
iagnosis  (of  emphysema)  should  only  be  considered  cer-
ain  when  dyspnoea  on  exertion,  of  insidious  onset,  not  due
o  bronchospasm  or  left  ventricular  failure,  appears  in  a
atient  who  has  some  of  the  physical  signs  of  emphysema
ogether  with  chronic  bronchitis  or  asthma.’’.14 The  CIBA
uest  Symposium  in  195915 and  the  American  Thoracic  Soci-
ty  Committee  on  Diagnostic  Standards  in  1962,16 were  two
andmark  meetings  that  deﬁned  the  components  of  COPD.  In
he  70s  the  risks  of  smoking,  the  accelerated  rate  of  decline
n  FEV1 in  susceptible  smokers,  and  the  effects  of  smok-
ng  cessation  on  lung  function  were  elegantly  described  by
letcher  et  al.17 During  the  80s,  focus  was  given  to  exa-
erbations,  prophylactic  antibiotic  therapy  and  prevention.
he  standards  for  oxygen  use  in  patients  with  advanced
OPD  and  chronic  respiratory  failure  were  also  deﬁned  in
his  decade.  During  the  late  90s  there  was  a  marked  evo-
ution  in  COPD  concepts,  individual  and  social  approaches,
nd  guideline  development.  There  was  the  emergence  of
ld  and  new  inhaled  drugs,  such  as  short-  and  long-acting
2-agonists  (SABAs  and  LABAs),  and  the  recognition  of  the
ole  of  corticosteroids,  smoking  cessation  and  pulmonary
ehabilitation  in  the  treatment  of  COPD,  when  there  was
till  clinical  confusion  between  asthma  and  COPD  in  terms
f  diagnosis  and  treatment.
It was  not  until  the  early  XXI  century  that  asthma  and
OPD  were  recognized  as  distinct  pulmonary  obstructive  dis-
ases,  although  the  Asthma-COPD  Overlap  Syndrome  (ACOS)
as  features  of  both  pathologies.  During  the  ﬁrst  decade
f  the  XXI  century,  the  role  of  each  pharmacological  class,
amely  long-acting  muscarinic  antagonists  (LAMAs)  and
nhaled  corticosteroids  (ICSs),  in  COPD  was  established.18
ABAs  were  recognized  as  efﬁcient  in  symptom  relief,  in
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mproving  quality  of  life  and  exercise  tolerance,  and  in
reventing  exacerbations.  Corticosteroids,  on  the  other
and,  have  been  considered  to  have  a modest  global  effect
n  COPD,  and  their  use  remains  controversial  in  stable
atients,  in  particular  due  to  evidence  of  increased  risk
f  pneumonia.19 The  central  role  of  tobacco  on  COPD  was
trengthened,  and  widespread  smoking  cessation  campaigns
nd  programs  were  implemented.  Techniques  such  as  lung
olume  reduction  (surgical  or  endoscopic)  and  transplanta-
ion  were  established  for  a  small  number  of  COPD  patients.
fter  2000,  the  understanding  of  the  social  costs  of  COPD
nd  the  elevated  disease-associated  morbidity  and  mortal-
ty  --  higher  than  in  asthma  --  led  to  population-based  studies
o  determine  its  prevalence  worldwide  and  its  impact  on
ortality  in  developed  countries.  Although  COPD  prevalence
aries  across  countries,  ranging  from  7.8%  to  19.7%,  and
cross  different  groups  within  countries,  it  is  one  of  the  most
mportant  causes  of  morbidity  and  mortality  worldwide.10
ike  hypertension  or  type  2  diabetes,  COPD  is  a  chronic  dis-
ase,  associated  to  modiﬁable  risk  factors,  high  morbidity
nd  increased  healthcare  costs,  and  should  thus  be  a  tar-
et  for  disease  control  strategies.  However,  and  contrary
o  hypertension  or  type  2  diabetes,  these  strategies  are
ore  difﬁcult  to  implement  in  COPD  given  the  difﬁculty  in
stablishing  objective  criteria  that  may  predict  outcomes
r  decrease  disease  risk.  Moreover,  indicators  of  disease
ontrol  and  modiﬁers  of  disease  progression  are  still  to  be
eﬁned.
After  2010,  a considerable  effort  was  made  to  establish
ifferent  COPD  phenotypes,20 and  GOLD  2011  proposed  dif-
erent  COPD  stages.21 Recently,  and  in  contrast  with  GOLD
uidelines,  it  has  been  suggested  that  COPD  management
eeds  to  be  centered  on  disease  stratiﬁcation  based  on  the
isk  of  exacerbations  and  dyspnea  symptoms.22 ICS  ﬁnally
ound  their  niche  in  COPD,  and  are  currently  recommended
or  patients  at  high  risk  of  exacerbation,  whilst  the  addition
f  a  second  bronchodilator  is  recommended  for  symptomatic
atients.10,22
COPD  in  now  recognized  as  a  systemic  disease  with
ulmonary,  cardiovascular,  metabolic  and  musculoskeletal
mplications.
nitial assessment and symptom control
here  are  currently  no  biomarkers  to  assess  the  onset  of
OPD,  determine  disease  activity  or  severity  or  predict  prog-
osis.  Given  the  documented  poor  correlation  between  FEV1
nd  symptoms/QoL  in  COPD  patients,1--5 several  guidelines
ave  recognized  the  need  to  incorporate  non-spirometric
easures  in  COPD  assessment  and  in  determining  thera-
eutic  options.6,7 Current  GOLD  guidelines  recommend  a
omprehensive  assessment  of  COPD,  including  symptoms,
sing  validated  questionnaires  such  as  the  modiﬁed  Medical
esearch  Council  Dyspnea  Scale  (mMRC),  the  Clinical  COPD
uestionnaire  (CCQ)8 and  the  COPD  Assessment  Test  (CAT),9
egree  of  airﬂow  limitation,  risk  of  exacerbations  and  exist-
nce  of  co-morbidities.10 Other  variables  that  should  be
aken  into  account  in  a  comprehensive  assessment  of  COPD
re  physical  activity  restrictions,5 particularly  important
ecause  exercise  capacity  and  functional  status  predict  exa-
erbations,  hospitalizations,  and  mortality.11 The  overall
d
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sCOPD  control:  Can  a  consensus  be  found?  
impact  of  COPD  in  a  patient’s  QoL  should  also  be  assessed.
Some  authors  suggest  that  for  the  assessment  of  symptom
control,  clinical  history,  symptoms  and  spirometry  should  all
be  used.23
What  is  controlled  COPD  disease?
One  possible  deﬁnition  is  ‘‘A  patient  with  COPD  is  considered
to  be  well  controlled  if,  during  follow-up,  show  minimal  or
no  symptoms,  no  acute  exacerbations  have  occurred  since
the  last  follow-up  visit,  and  no  impairment  in  QoL  has  been
seen  while  receiving  the  current  treatment’’.12
However,  in  the  absence  of  objective  criteria,  it  is
difﬁcult  to  clearly  deﬁne  controlled  disease.  Is  there  an
intermediate  stage  between  controlled  disease  and  uncon-
trolled  disease?  Not  at  present.  Is  a  patient  who  has  had
one  exacerbation  equally  controlled  or  uncontrolled  com-
pared  with  a  patient  who  has  experienced  two  or  more
exacerbations?  At  the  moment,  this  question  cannot  be
answered.  Moreover,  since  COPD  is  a  chronic  progressive  dis-
ease,  one  cannot  expect  a  patient  to  remain  completely
asymptomatic.  The  physician’s  goal  is  to  control  the  dis-
ease  to  the  extent  it  can  be  controlled,  and  expectations  of
control  will  vary  according  to  the  individual  and  the  COPD
stage.
We  propose  that  patients  are  considered  to  be  well  con-
trolled  if  they  are  asymptomatic  or  show  a  decrease  in
symptoms  from  baseline,  have  stable  or  decreased  decline
of  pulmonary  function,  show  an  increased  tolerance  to  exer-
cise,  have  no  exacerbations  and  the  best  possible  QoL.
Initial  assessment
A  clinical  diagnosis  of  COPD  should  be  considered  in  any
patient  who  has  dyspnea,  chronic  cough  or  sputum  produc-
tion,  and  a  history  of  exposure  to  risk  factors  for  the  disease,
with  spirometry  being  required  to  establish  a  diagnosis.10
Although  spirometric  screening  of  asymptomatic  individuals
is  not  supported  by  evidence,  in  individuals  over  40  years
old  and  with  a  smoking  history  (>10  packs-year),  spirom-
etry  may  be  performed  with  the  aim  of  early  diagnosis.24
However,  as  already  stated  above,  there  is  a  documented
poor  correlation  between  FEV1 and  symptoms/QoL  in  COPD
patients.1--5 Spirometry  is  not  recommended  during  exa-
cerbations  because  it  can  be  difﬁcult  to  perform  and
measurements  are  not  accurate  enough.10
Additional  tests  that  can  be  useful  in  the  differen-
tial  diagnosis  and  characterization  of  COPD  manifestations
include  chest  X-ray,  measurement  of  lung  volumes  and
diffusing  capacity  for  carbon  monoxide  (DLCO),  and  oxy-
gen  saturation  levels  at  rest  and  during  exercise.5 The
use  of  Computed  Tomography  (CT)  in  the  assessment  of
patients  with  COPD  can  provide  quantitative  measures  of
both  emphysema  and  airway  disease5 and  it  is  useful  in
identifying  the  presence  of  previously  unrecognized  radio-
graphic  bronchiectasis  that  appears  to  be  associated  with
longer  exacerbations  and  increased  mortality.10We  propose  that  initial  disease  severity  assessment
should  include  smoking  history,  symptoms  (particularly
dyspnea),  spirometry,  history  of  exacerbations,  systemic
manifestations,  exercise  tolerance,  daily  impact  of  the
t
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isease  (health  related  QoL  and  health  status)  and  mortality
isk.
pirometry
pirometry  is  required  to  establish  a diagnosis  of  COPD:
he  presence  of  a  post-bronchodilator  FEV1/FVC  <  0.70  con-
rms  the  presence  of  persistent  airﬂow  limitation  and  is
ecessary  for  the  diagnosis  of  COPD.  FEV1 is  one  of  the  mark-
rs  of  disease  severity,  whereas  FEV1 decline,  among  other
iomarkers,  should  be  evaluated  to  determine  disease  activ-
ty,  related  to  disease  progression  and  inﬂammation.25 In
act,  the  decline  of  pulmonary  function  across  time  may  be
 marker  of  uncontrolled  disease  and  thus  this  should  be
aken  into  account.  A  normal  value  for  spirometry  effec-
ively  excludes  the  diagnosis  of  clinically  relevant  COPD.10
owever,  the  documented  poor  correlation  between  FEV1
nd  symptoms/QoL  in  COPD  patients,1--5 raises  doubt  about
he  real  importance  of  spirometry  as  a  tool  for  assessing
OPD  control.  Spirometry  should  be  used  in  symptomatic
atients  with  risk  factors  for  COPD.23
We  agree  that  spirometry  is  required  to  establish  a  diag-
osis  of  COPD.
We  propose  that  spirometry  is  still  performed  once  a  year
or  monitoring  COPD  until  new  evidence  or  disease  markers
re  available.
yspnea
yspnea  is  a  major  cause  of  disability  in  COPD,10 it  is
he  most  prevalent  symptom  among  patients  with  respira-
ory  diseases,26 an  independent  predictor  of  mortality  in
atients  with  COPD,4,26 and  associated  with  decreased  exer-
ise  performance,27 physical  performance,  quality  of  life,
nxiety  and  depression.3 It  is  the  most  restrictive  symp-
om  of  COPD  and  reﬂects  better  overall  disease  impact  than
pirometry.3 Unfortunately,  there  are  no  objective  measures
f  dyspnea.  GOLD  guidelines  recommend  the  use  of  the
bove  mentioned  validated  questionnaires.10 Again,  all  of
hese  are  subjective,  but  it  is  not  possible  to  accurately
tratify  a  subjective  symptom.  Despite  their  weaknesses,
hen  used  correctly,  mMRC,  CCQ  and  CAT  are  useful  and
easible  in  clinical  practice,  and  can  be  used  in  all  consulta-
ions,  both  in  primary  care  and  hospital  settings.  However,
MRC  may  be  preferable,  given  that  it  is  simpler  to  use  and
s  a better  predictor  of  all-cause  mortality  in  COPD  patients
ompared  to  CCQ  and  CAT.28
Although  there  is  no  doubt  that  dyspnea  is  the  cardi-
al  symptom  of  COPD,  others  such  as  cough  and  sputum
roduction  should  not  be  underestimated.  Cough  is  often
eglected  by  healthcare  professionals  and  ignored  in  pop-
lation  studies,  but,  together  with  sputum  production,  has
 negative  impact  on  the  patient’s  QoL.  A  large  study  in
atients  with  severe  COPD  showed  that  58.7%  of  patients
xperience  mild  to  severe  cough  and  63.6%  mild  to  severe
putum  production.29 Moreover,  chronic  mucus  hypersecre-
ion  is  signiﬁcantly  associated  with  FEV1 decline  and  risk  of
ubsequent  hospitalization  because  of  COPD,30 and  increases
he  risk  of  pneumonia31 therefore,  should  not  be  overlooked
ut  be  part  of  symptom  assessment.
1 M.  Guimarães  et  al.
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Table  1  Some  currently  used  deﬁnitions  of  an  exacerbation
of COPD.
Deﬁnition  Source
A  rapid  and  sustained  worsening  of  symptoms
beyond  normal  day-to-day  variations
6
An  acute  event  characterized  by  a  worsening
of the  patient’s  respiratory  symptoms  that  is
beyond  normal  day-to-day  variations  and
leads  to  a  change  in  medication
10
An  acute  deterioration  of  symptoms  and  lung
function,  which  often  results  in  respiratory
failure
37
An  increase  in  symptom  intensity  occurring
after  a  certain  period  of  time  since  the  last
exacerbation
39
Presence,  for  at  least  two  consecutive  days,  of
the following  symptom  patterns:  either  two
or more  of  three  major  symptoms  (increase
in dyspnea,  sputum  purulence,  and  increased
sputum  volume);  or  any  one  major  symptom
together  with  any  one  of  the  following  minor
symptoms  --  increase  in  nasal  discharge,
wheeze,  sore  throat,  cough,  or  fever
41
A  sustained  worsening  of  the  patient’s
condition,  from  the  stable  state  and  beyond
normal  day-to-day  variations,  that  is  acute
in onset  and  necessitates  a  change  in  regular
medication  in  a  patient  with  underlying
COPD
42
A  sustained  worsening  of  the  patient’s
condition  from  the  stable  state  and  beyond
normal  day-to-day  variations  that  is  acute  in
onset  and  may  warrant  additional  treatment
in a  patient  with  underlying  COPD
43
A  worsening  of  dyspnea,  cough  or  sputum;
dyspnea  ≥4  on  a  0--10  scale;  normal  chest
radiograph;  WBC  count  >9000  cells/dL  or
CRP  >  10  mg/dL
44
A  complex  of  respiratory  events  (i.e.  cough,
wheezing,  dyspnea  or  sputum  production)
lasting  >3  days
45
Increased  dyspnea,  sputum  production,  and
sputum  purulence
46
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We  recommend  that  COPD  symptom  assessment  should
ocus  mainly  on  dyspnea,  although  cough  and  sputum
roduction  should  not  be  underestimated.  Assessment  of
yspnea  may  be  achieved  by  using  mMRC,  CCQ  and  CAT  at
very  consultation,  but  if  this  is  not  possible,  preference
hould  be  given  to  mMRC.
hysical  activity
nactivity  is  associated  with  a  greater  lung  function  decline,
hich  can  be  partially  reversed  by  exercise,32 and  low
evels  of  physical  activity  predict  all-cause  mortality  in
atients  with  COPD.33 Current  guidelines  recommend  that
ll  patients  with  COPD  should  engage  in  regular  physical
ctivity  regardless  of  disease  severity,6,7,10,20,24 also  recom-
ending  that  any  training  program  should  be  tailored  to
ach  individual  patient.
We  agree  with  current  guidelines  on  physical  activity  rec-
mmendations  for  COPD  patients.
xacerbations
xacerbations  contribute  to  the  overall  severity  of
OPD,10,24 to  the  pulmonary  function  decline  and  the
mpairment  of  QoL,12,34--37 to  morbidity38 and  mortality.34--38
xacerbations  also  increase  the  risk  of  cardiovascular  dis-
ase,  of  developing  further  exacerbations,  contribute  to
educe  muscle  mass,35 limit  physical  activity,35,36 increase
nxiety,  depression,  work  absenteeism,  and  healthcare
osts.35,37 Exacerbations  may  occur  regardless  of  the  degree
f  functional  impairment,12,36,39,40 and  it  has  been  shown
hat  mild  and  moderate  exacerbations,  often  unreported
nd  thus  untreated,  also  affect  health  status.12,36 Therefore,
t  is  important  to  predict  and  promptly  identify  exacerba-
ions,  and  assess  their  severity  and  number,12,34 in  order
o  appropriately  manage  them,  prevent  hospitalization,34,35
ncrease  the  patient’s  QoL  and  reduce  the  high  costs  associ-
ted  with  their  treatment.24
The  ﬁrst  step  to  achieving  these  goals  would  be  through
 consensus  deﬁnition  of  exacerbation.  However,  in  the
bsence  of  easily  quantiﬁable  criteria,35 there  is  no  exact
r  consistent  deﬁnition  of  exacerbation,38 and  several  deﬁ-
itions  have  been  implemented6,10,37,39,41--46 Table  1.  Also,  a
onsensual  and  universal  classiﬁcation  system  to  assess  the
everity  of  an  exacerbation  is  lacking,  although  some  have
een  proposed.10,42,43
The  question  of  how  to  predict  or  identify  a  potential
xacerbation  during  a  routine  follow-up  visit  remains  unan-
wered.  What  are  the  known  risk  factors?  Are  there  objective
iological  and  clinical  markers?  Are  questionnaires  helpful?
Numerous  risk  factors  for  the  occurrence  of  exacer-
ations  are  identiﬁed.10,12,36,37 GOLD  recommends  several
bjective  tests  to  assess  the  severity  of  an  exacerbation,10
nd  other  authors  suggest  additional  assessments.12,36 Ques-
ionnaires  such  as  the  mMRC,  CCQ  and  CAT11 may  also  be
elpful  in  this  evaluation.We  propose  that  an  exacerbation  should  be  deﬁned  as
 sustained  acute/subacute  worsening  of  the  severity  or
requency  of  symptoms  such  as  dyspnea,  cough  or  sputum
roduction,  with  increased  QoL  impairment,  lasting  at  least
t
c
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sCOPD -- Chronic Obstructive Pulmonary Disease; WBC -- White
Blood Cell; CRP -- C-reactive protein.
 days,  which  prompts  the  patient  to  seek  medical  attention
r  leads  to  a  change  in  medication.
uality  of  Life
ll  the  recommended  QoL  questionnaires  have  weak
oints.11,12 They  are  not  thorough,  and  there  may  be  oth-
rs  symptoms  and  factors  that  inﬂuence  QoL.  Also,  patients
end  to  dislike  completing  questionnaires,  preferring  instead
o  talk  to  their  doctor,  and  clinicians  may  also  ﬁnd  it  difﬁ-
ult  to  complete  questionnaires  in  daily  clinical  practice.11
urrently,  there  are  no  alternative  means  for  assessing
ymptoms  and  QoL,  but  it  would  be  desirable  to  have  a  more
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comprehensive,  yet  easy  and  quick  to  use,  assessment  of  all
the  factors  that  impair  these  patients’  global  health.
Non-pharmacological measures to achieve
COPD control
Recommended  non-pharmacologic  management  of  COPD
depends  on  the  individualized  assessment  of  symptoms
and  exacerbation  risk.  GOLD  proposes  as  essential  smoking
cessation,  physical  activity,  inﬂuenza  and  pneumococ-
cal  vaccination  for  all  patient  groups,  and  pulmonary
rehabilitation  for  B,  C  and  D  patients.10 Additional
non-pharmacological  measures  include  patient  education,
an  appropriate  diet,12,47 oxygen  therapy  and  ventilatory
support.47
Smoking  cessation
Smoking  cessation  has  the  greatest  capacity  to  inﬂuence  the
natural  history  of  COPD,24,48 it  is  the  most  effective  way  of
preventing  or  delaying  the  development  of  airﬂow  limitation
and  reducing  disease  progression,47 it  improves  symptoms
and,  at  the  moment,  it  is  the  best  intervention  to  decrease
COPD  associated  mortality.49 Therefore,  it  is  imperative  to
have  a  proper  and  adequate  support  structure  to  encourage
and  help  patients  to  quit  smoking.  However,  COPD  smok-
ers  require  special  support  in  order  to  quit  smoking,  and  it
has  been  reported  that  33%  to  50%  of  COPD  patients  remain
smokers18,50 despite  being  strongly  advised  to  quit  smoking
due  to  their  COPD.  Cigarette  smoking  should  be  regarded
as  a  chronic  relapsing  disease,  and  the  role  of  the  clini-
cian  is  to  help  smokers  achieve  abstinence  (remission),  by
recognizing  that  relapses  may  occur.  Tobacco  dependence
treatments  are  cost-effective  relative  to  other  medical  and
disease  prevention  interventions.51 Although  brief  tobacco
dependence  treatment  has  been  found  to  be  effective,  there
is  a  strong  dose--response  relationship  between  the  intensity
of  tobacco  dependence  counseling  and  its  effectiveness.52
Nicotine  replacement  therapy,  as  well  as  pharmacothe-
rapy  with  varenicline  or  bupropion,  reliably  increases  long-
term  smoking  abstinence  rates.10 An  intensive  and  prolonged
relapse  prevention  program  is  also  recommended.24,47
Vaccination
In  the  age  groups  ≥50  and  ≥65,  hospitalization  for  Commu-
nity  Acquired  Pneumonia  (CAP)  represents  5.5%  and  7.0%,
respectively,  of  total  admissions  for  all  causes  in  Portugal.53
Therefore,  inﬂuenza  and  pneumococcal  vaccination  are
recommended.6,7,10,20,24,53,54 In  Portugal  two  pneumococcal
vaccines  are  available,  a  pneumococcal  polysaccharide  vac-
cine  23-valente  and  a  pneumococcal  conjugate  vaccine
13-valente.  COPD  patients  must  follow  the  dosing  schedule
suggested.53
Physical  activityPatients  with  COPD  have  signiﬁcantly  lower  levels  of  physical
activity  compared  to  healthy  controls,55 and  breathlessness
on  exertion,  the  primary  symptom  limiting  exercise,  leads
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o  a  reduced  physical  activity  in  these  patients.56 Physical
ctivity  is  dramatically  reduced  during  and  after  hospital-
zation  due  to  a  COPD  exacerbation,  and  this  initiates  a
icious  cycle,  since  increased  duration  of  inactivity  pro-
otes  new  exacerbations  and  hospitalizations.57 Moreover,
vidence  suggests  that  reduced  physical  activity  predisposes
o  greater  incidence  of  cardiovascular  diseases,  type  2  dia-
etes,  cancer,  dementia,  physical  disability  and  depression,
onditions  that  are  common  co-morbidities  of  COPD.58 Exer-
ise  training  programs  improve  exercise  capacity,  dyspnea
nd  fatigue.  Lower-limb  training  (e.g.,  walking  or  static
icycle)  is  optimally  effective  and  provides  the  greatest
hort-term  beneﬁt.  It  improves  exercise  tolerance,  reduces
he  number  of  exacerbations  and  hospitalizations,  and
mproves  QoL.  The  amount  of  regular  maintenance  physical
ctivity  recommended  is  walking  30--45  min/day  three-times
 week  followed  by  climbing  up  and  down  the  stairs  sev-
ral  times  for  5  minutes.12 However,  the  amount  of  regular
hysical  activity  needed  to  obtain  a signiﬁcant  effect  on
dmissions  due  to  COPD  is  equivalent  to  walking  or  cycling
or  2  h  per  week.59
COPD  patients  are  often  limited  in  their  ability  to  per-
orm  exercise  and  several  adjunct  therapies  have  been
roposed  for  use  during  exercise,  namely  Non-Invasive  Venti-
atory  Support  (NIVS)  and  Heliox.27 Also,  increase  in  exercise
apacity  with  rehabilitation  programs  in  combination  with
ehavioral  change  may  have  the  potential  to  increase  phys-
cal  activity  in  patients  with  COPD.60 Indeed,  increasing  the
xercise  capacity  of  patients  with  COPD  may  be  insufﬁcient
o  increase  participation  in  leisure  time  activity.  Interven-
ions  including  self-monitoring  of  activity  behavior  using
ctivity  monitors  in  combination  with  behavioral  counseling
n  patients  with  COPD  might  have  the  potential  to  change
hysical  activity  behavior.  Key  components  that  increase  the
ffectiveness  of  behavioral  interventions  have  already  been
ummarized  in  several  meta-analyses,  international  guide-
ines  and  reviews.61
ulmonary  rehabilitation
ulmonary  rehabilitation  (PR)  is  a  comprehensive  interven-
ion  based  on  a  complete  patient  assessment  followed  by
ndividual  therapies,  which  include,  but  are  not  limited
o,  exercise  training,  education,  and  behavior  change.
t  is  designed  to  improve  the  physical  and  psychological
ondition  of  people  with  chronic  respiratory  disease  and
o  promote  the  long-term  adherence  to  health-enhancing
ehaviors.62
Exercise  training  is  considered  to  be  a  crucial  element  of
he  rehabilitation  program.  It  enhances  exercise  tolerance
ainly  through  improvement  of  skeletal  muscle  function
nd  reduction  of  ventilatory  requirements  during  exercise,
nd  increases  functional  performance  through  physiologic
mprovements,  enhanced  movement  efﬁciency,  and  perhaps
ncreased  self-efﬁcacy.63 The  length  of  the  exercise  train-
ng  component  ranges  from  4  to  10  weeks  and  the  longer
he  program  continues,  the  more  effective  the  results.10ome  authors  suggest  a  minimum  duration  of  8  weeks  with
 minimum  frequency  of  three  training  sessions  a  week.64
ower-limb  training  is  the  most  important  goal  to  achieve
uring  pulmonary  rehabilitation  of  these  patients.12,47
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However,  it  is  of  the  utmost  importance  to  maintain  the
eneﬁts  of  an  exercise  training  program  in  the  long  term,
hich  will  perhaps  have  an  impact  on  truly  modifying  the
ong-term  non-respiratory  consequences  of  COPD.65
Rehabilitation  has  several  beneﬁts:  (a)  improves  patient-
eported  outcomes,  such  as  symptoms  and  QoL63;  (b)  leads
o  psychological  improvements66;  and  (c)  decreases  the  use
f  health  care  resources.64 PR  beneﬁts  appear  to  decline  12
onths  after  the  end  of  the  intervention.67
Further  research  should  focus  on  strategies  such  as
ehavioral  changes,  to  ensure  the  long-term  beneﬁts  of
ehabilitation  programs  for  patients  with  COPD.
It  is  consensual  that  non-pharmacological  measures  have
 pivotal  role  in  disease  control.  They  are  useful,  necessary
nd  effective.
However,  we  acknowledge  that  these  measures  are  difﬁ-
ult  to  implement  at  an  individual  level,  not  only  due  to  their
mpact  on  lifestyle  changes  but  also  because  they  are  often
nderestimated  by  patients.  The  lack  of  nationwide  infor-
ation  campaigns  and  concerted  strategies  also  hamper  the
mplementation  of  these  measures.
We  propose  that  nationwide  campaigns  and  strategies
romoting  the  necessary  conditions  to  design  an  optimized
ersonalized  plan  for  each  patient,  considering  disease
tratiﬁcation,  patient  teaching,  coordination  with  rehabil-
tation  facilities,  rehabilitation  medicine,  gymnasiums,  and
ther  possible  support  structures,  should  be  implemented.
harmacological measures to achieve COPD
ontrol
ecommendations  for  therapy  are  set  forth  by  interna-
ional  guidelines.6,7,10,24 There  are  three  main  therapeutic
oals  in  COPD:  (1)  reduce  symptoms;  (2)  reduce  risk,
nd  (3)  improve  prognosis.10 Beyond  the  already  discussed
on-pharmacological  measures,  several  pharmacological
pproaches  are  currently  available  to  manage  stable
OPD.  The  choice  of  pharmacotherapy  should  be  based
n  symptoms,  exacerbations  and  severity  of  obstruction.
nadequately  controlled  symptoms  or  the  presence  of  exa-
erbations  may  modify  therapeutic  stratiﬁcation.
Bronchodilators  are  the  pivotal  therapy  in  the  control
f  COPD.  According  to  the  GOLD  guidelines,  inhaled  for-
ulations  are  preferable  to  systemic  formulations  due  to
ess  adverse  events  and  increased  efﬁcacy.  Also,  long  act-
ng  bronchodilators  are  preferable  to  short  acting  ones.
he  choice  between  a  LABA  or  a  LAMA  depends  on  avail-
bility  and  individual  response  to  therapy.  The  association
f  bronchodilators  of  different  classes,  e.g.  LABA  +  LAMA,
ay  improve  efﬁcacy  and  safety  compared  to  dose  adjust-
ent  of  a  bronchodilator  in  monotherapy.  Indeed,  a  recently
pproved  ﬁxed-dose  LABA/LAMA  combination  was  associ-
ted  with  the  concept  of  disease  control.68--71 ICS  should
nly  be  used  in  patients  at  higher  risk  of  exacerbations  and
ever  as  monotherapy,  only  added  after  trials  of  one  or  more
ong-acting  bronchodilators,  and  only  in  frequent  exacer-
ators  (≥2  exacerbations  per  year  or  1  exacerbation  with
ospitalization).10 In  addition,  and  according  to  some  data,
 FEV1 <  60%  should  also  be  taken  into  consideration.18
However,  the  recognized  heterogeneity  of  COPD  has  ther-
peutic  implications.  The  distribution  of  variables  such  as
o
i
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everity  of  airﬂow  limitation,  degree  of  breathlessness,
ealth  status,  presence  of  co-morbidities,  exercise  capacity,
nd  number  of  exacerbations  in  the  previous  year  has  been
eported  to  be  highly  variable  within  each  GOLD  stage.1
lso,  classiﬁcation  of  disease  severity  by  airﬂow  obstruc-
ion  has  been  challenged  not  only  by  GOLD  guidelines10 but
lso  by  other  studies.72,73 This  variability  precludes  a  gen-
ral  therapeutic  approach  for  COPD  patients.  Indeed,  the
panish  guidelines  for  treatment  of  COPD  proposes  four  clin-
cal  phenotypes  on  which  pharmacological  treatment  should
e  based,  and  recommends  different  treatment  options
epending  on  these  four  phenotypes.74,75 These  guidelines
ave  been  recently  updated,  with  some  modiﬁcations.20
We  suggest  a  pharmacological  therapeutic  approach
ased  on  GOLD  stages  Table  2.
Pharmacological  treatment  should  not  be  given  to  asymp-
omatic  GOLD  A  patients,  but  a  SABA  or  a  short-acting
uscarinic  antagonist  (SAMA)  can  be  used  as  rescue  med-
cation,  if  needed.  However,  if  patients  have  a  low  FEV1
50%  ≤  FEV1≤  80%  predicted),  evidence  of  hyperinﬂation,
nd  mMRC  =  1,  a  long  acting  bronchodilator  for  symptom
elief  is  recommended.10 For  GOLD  B  patients,  the  choice  of
ABA  or  LAMA  should  be  made  according  to  efﬁcacy  in  each
ndividual  patient.  However,  since  previous  exacerbations
re  the  most  reliable  predictors  of  future  exacerbations,
he  choice  of  a  single  long-acting  bronchodilator  should  take
nto  account  the  decreased  risk  of  exacerbations,76 and,  in
his  context,  a  LAMA  should  be  the  ﬁrst  choice.  The  combi-
ation  LABA  +  LAMA  is  recommended  for  more  symptomatic
atients.  Maintenance  of  monotherapy  before  switching  to
ual  bronchodilation  should  be  based  on  symptoms,  risk
actors,  and  possibility  of  improving  non-pharmacological
easures.  There  is  no  evidence  concerning  ICS  treatment
n  patients  with  FEV1 >  60%  predicted.10 For  GOLD  C  and  D
atients,  the  combination  LABA  +  LAMA  should  be  the  ﬁrst
hoice;  for  those  patients  with  frequent  exacerbations  (≥2
xacerbations/year,  or  1  exacerbation  with  hospitalization),
he  ICS/LABA  combination  should  be  preferred.  Triple  ther-
py  with  ICS  +  LAMA  +  LABA  should  be  considered  for  patients
ith  frequent  exacerbations  who  continue  to  have  symp-
oms.  Although  there  have  been  some  developments  on  the
nclusion  of  eosinophilic  counts  in  the  decision  tree  to  pre-
cribe  ICS,  this  paper  does  not  discuss  this  issue,  which  is
uly  addressed  elsewhere.77
There  are  some  additional  therapies  not  mentioned  in
able  2  that  are  available  and  may  be  useful  in  certain
atients.  In  patients  with  severe  hereditary  -1  antitrypsin
eﬁciency  (ZZ  genotype),  -1  antitrypsin  replacement  ther-
py  may  be  considered  for  young  patients  with  established
mphysema  who  meet  the  established  laboratory  criteria.10
owever,  this  therapy  is  very  expensive  and  is  not  avail-
ble  in  most  countries.10 The  National  Institute  for  Health
nd  Care  Excellence  (NICE)  guidelines  do  not  recom-
end  replacement  therapy  in  patients  with  -1  antitrypsin
eﬁciency.6 Another  class  of  potentially  useful  drugs  is
ucolytic  agents,  such  as  N-acetylcysteine  (NAC)  or  carbo-
ysteine,  but  their  effect  on  reducing  exacerbations  have
ot  been  consistent  across  studies,78--85 and  seem  to  depend
n  dose  and  COPD  severity.  Therefore,  their  generalized  use
s  not  recommended.  Erdosteine  seems  to  be  associated  with
 signiﬁcant  beneﬁt  in  terms  of  symptom  amelioration,86 but
arger  long-term  studies  with  fully  validated  endpoints  are
COPD  control:  Can  a  consensus  be  found?  
Table  2  Proposed  pharmacological  therapeutic  approach
according  to  GOLD  stage.
GOLD  stage  Therapeutic  approach
First  choice Other  options
A  (FEV1≥  80%
or
50%  ≤  FEV1≤  80%
predicted,
0 ≤  mMRC  ≤  1,
CAT  <  10)
SABA  or  SAMA
SOS  only
LABA  or  LAMA
or
SABA  +  SAMA
B (FEV1≥  80%  or
50%  ≤  FEV1≤  80%
predicted,
mMRC  ≥  2,
CAT  ≥  10)
Few  symptoms
More
symptomatic
(mMRC  ≥  3,  or
already  in
monotherapy
without
symptom
relief,  or  at
least  1
exacerbation)
LABA  or  LAMA
LABA  +  LAMA
LABA  +  LAMA
C (FEV1 <  50%
predicted,
0  ≤  mMRC  ≤  1,
CAT  <  10)
LABA  +  LAMA  or
ICS  +  LABAa
ICS  +  LAMAa
D  (FEV1 <  50%
predicted,
mMRC  ≥  2,
CAT  ≥  10)
LABA  +  LAMA
ICS  +  LABA  +  LAMAa
Note: Other pharmacological therapies, namely xanthines,
aminophylline and theophylline, are available and may be useful
in some patients. GOLD -- Global initiative for chronic Obstruc-
tive Lung Disease; mMRC -- modiﬁed Medical Research Council
dyspnea scale; CAT -- COPD Assessment Test; SABA -- short-acting
beta agonist; SAMA -- short-acting muscarinic antagonist; LABA
-- long acting 2-agonist; LAMA -- long-acting muscarinic antag-
onist; ICS -- inhaled corticosteroid.
a Patients with frequent exacerbations (≥2 exacerba-
tions/year, or 1 exacerbation with hospitalization) require
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atreatment with ICS.
required87 before  a  clear  recommendation  can  be  offered.
Theophylline,  a  methylxanthine,  should  only  be  considered
if  other  long-term  treatment  bronchodilators  are  unavail-
able  or  unaffordable,  or  in  patients  who  are  unable  to  use
inhaled  therapy.  Intravenous  methylxanthines  (theophylline
or  aminophylline)  should  only  be  used  in  the  management  of
exacerbations  when  there  is  insufﬁcient  response  to  short-
acting  bronchodilators.6,10,24 The  available  evidence  on  the
efﬁcacy  of  immunostimulating  agents  is  currently  not  sup-
10portive  of  a  recommendation.
We  agree  that  bronchodilation  is  the  cornerstone  of  COPD
treatment.  COPD  is  a  highly  variable  disease,  and  each
individual  patient  will  have  different  therapeutic  needs.
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herefore,  it  is  imperative  to  tailor  therapy  to  each  patient,
iven  an  optimized  therapeutic  approach  will  not  only
mprove  symptoms  but  also  increase  compliance.  We  fur-
her  propose  that  exacerbator  phenotypes  modulate  COPD
everity  within  each  GOLD  stage  and  should  therefore  have
 more  aggressive  treatment  approach.
onitoring
everal  key  points  have  been  proposed  to  be  included  on
he  follow-up  of  COPD  patients.12 One  important  aspect  is
hat  COPD  patients  often  underestimate  their  symptoms,
amely  dyspnea,  since  they  adapt  their  lifestyle  to  cope
ith  it,  which  may  lead  to  undertreatment.  Therefore,  mea-
uring  symptoms  in  a  routine  manner  using  questionnaires,
an  lead  to  a  better  understanding  of  the  patient’s  overall
linical  status  and  hence  to  the  adjustment  of  treatment
ccordingly.  In  recent  years,  the  goal  of  COPD  manage-
ent  has  shifted  toward  optimizing  symptom  control  and
educing  future  risk,  such  as  exacerbations,  mortality,  and
o-morbidities,  as  well  as  the  long-term  consequences  of
OPD.  While  prevention  and  treatment  of  symptoms  may
ot  preclude  long-term  lung  function  decline,  symptom  con-
rol  could  provide  measurable  improvements  in  other  key
utcomes.11
There  are  no  clear  recommendations  concerning  when
OPD  patients  should  be  referred  to  a  pulmonology  outpa-
ient  department,  but  some  guidelines  suggest  reasons  for
eferral,  e.g.  FEV1 <  50%  predicted,  frequent  exacerbators,
-1  antitrypsin  deﬁciency,  ACOS,  or  uncertain  diagnosis.6,7,24
In  the  absence  of  clear  recommendations,  we  propose
hat  a  key  aspect  of  COPD  monitoring  resides  in  a  multi-
isciplinary  approach,  with  Primary  Care  having  a  central
ole  in  the  monitoring  and  follow-up  of  the  majority  of  sta-
le  COPD  patients.  Primary  Care  should  be  responsible  for
ecognizing  when  a  patient  should  be  referred  to  a  speciﬁc
pecialty,  e.g.  Pulmonology,  Cardiology,  Internal  Medicine  or
hysical  Rehabilitation,  and  henceforth  the  coordinated  and
ntegrated  management  of  comorbities  should  be  achieved.
There  is  no  established  time  interval  between  follow-
p  consultations,  and  this  should  be  guided  by  clinical
udgment.  We  recommend  that  a  stable  COPD  patient,
ith  no  exacerbations  and  who  complies  with  therapy,
ay  have  a  follow-up  consultation  every  6  months.  In
ll  follow-up  consultations  questionnaires  should  be  com-
leted,  especially  mMRC.  Annual  spirometric  assessment  is
ecommended,  especially  in  poorly  controlled  patients  and
requent  exacerbators.  Although  oximetry  is  useful,  it  is  con-
itioned  by  availability.
onclusions
resently,  it  is  not  possible  to  reach  a  consensus  regarding
OPD  control,  which  will  probably  be  difﬁcult  to  attain
ntil  a consensus  deﬁnition  of  ‘‘well-controlled  disease’’
s  achieved.  However,  this  deﬁnition  depends  not  only  on
 thorough  assessment  of  COPD  severity  and  symptoms,
ut  also  their  individual  and  social  impact,  which,  again,
re  lacking.  Initial  assessment,  monitoring  and  follow-up  of
OPD  patients  do  not  yet  have  clear  recommendations,  and
ew,  more  accurate,  instruments  to  assess  disease  control
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274  
re  missing.  Consensus  about  COPD  control  will  probably
ot  be  attainable  before  the  gap  between  disease  assess-
ent  and  disease  control  is  bridged.  Once  this  is  achieved,
t  may  pave  the  way  for  new  avenues  of  research  that  will
ventually  answer  the  current  questions.
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